Leo Zhang
Overview
Explore the profile of Leo Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ta D, Anthony A, Sliow A, Wan B, Zhang L, Zang L, et al.
Small
. 2025 Feb;
21(9):e2408941.
PMID: 39901509
SH-SY5Y neuroblastoma cells are widely used to model neurodegenerative disorders like Alzheimer's, Parkinson's, Huntington's, and Hereditary Sensory Neuropathy type 1A (HSN-1A), a peripheral nerve condition causing axon degeneration and sensory...
2.
Xu N, Zhang L, Larson S, Li Z, Anumba N, Daley L, et al.
Apert Neuro
. 2023 Sep;
3.
PMID: 37654427
No abstract available.
3.
Wu N, Mah C, Koentgen S, Zhang L, Grimm M, El-Omar E, et al.
Proc Nutr Soc
. 2021 Jun;
:1-11.
PMID: 34165053
Inflammatory bowel disease (IBD) is a group of immune-mediated disorders characterised by a chronic, relapsing-remitting inflammation predominantly affecting the gastrointestinal tract. IBD is incurable, affecting people in their most productive...
4.
Pham L, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al.
Clin Cancer Res
. 2018 Apr;
24(16):3967-3980.
PMID: 29666304
B-cell lymphoma-2 (BCL-2), an antiapoptotic protein often dysregulated in B-cell lymphomas, promotes cell survival and provides protection from stress. A recent phase I first-in-human study of the BCL-2 inhibitor venetoclax...
5.
Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, et al.
Blood Cancer J
. 2018 Mar;
8(3):33.
PMID: 29559616
No abstract available.
6.
Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, et al.
Clin Cancer Res
. 2017 Mar;
23(15):4212-4223.
PMID: 28348046
Patients with B-cell lymphomas often relapse after frontline therapy, and novel therapies are urgently needed to provide long-term remission. We established B-cell lymphoma patient-derived xenograft (PDX) models to assess their...
7.
Ahmed M, Zhang L, Nomie K, Lam L, Wang M
Oncotarget
. 2016 Jul;
7(36):58638-58648.
PMID: 27449094
Mutations and epigenetic alterations are key events in transforming normal cells to cancer cells. Mantle cell lymphoma (MCL), a non-Hodgkin's lymphoma of the B-cell, is an aggressive malignancy with poor...
8.
Wang M, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, et al.
Lancet Oncol
. 2015 Dec;
17(1):48-56.
PMID: 26640039
Background: Ibrutinib is approved in the EU, USA, and other countries for patients with mantle cell lymphoma who received one previous therapy. In a previous phase 2 study with single-agent...